FibroGen (FGEN) Issues Quarterly Earnings Results, Beats Expectations By $0.15 EPS

FibroGen (NASDAQ:FGEN) released its earnings results on Thursday. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.15, Fidelity Earnings reports. FibroGen had a negative net margin of 44.14% and a negative return on equity of 17.69%. The business had revenue of $23.90 million during the quarter, compared to analyst estimates of $20.44 million. During the same period in the prior year, the business earned ($0.50) earnings per share. The business’s quarterly revenue was down 25.1% on a year-over-year basis.

Shares of NASDAQ:FGEN traded down $9.28 during mid-day trading on Friday, hitting $36.39. The stock had a trading volume of 7,500,656 shares, compared to its average volume of 624,578. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.75 and a current ratio of 7.75. The company has a market cap of $3.93 billion, a PE ratio of -35.33 and a beta of 1.60. FibroGen has a 12-month low of $33.51 and a 12-month high of $68.55.

Several analysts recently commented on the stock. ValuEngine lowered shares of FibroGen from a “buy” rating to a “hold” rating in a research note on Friday. William Blair lowered shares of FibroGen from an “outperform” rating to a “market perform” rating in a research note on Friday. Mizuho reduced their price target on shares of FibroGen from $74.00 to $65.00 and set a “positive” rating for the company in a research report on Friday. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “strong-buy” rating and set a $55.00 price target for the company in a research report on Tuesday, April 30th. Finally, BidaskClub downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. One analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $68.50.

In related news, CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction that occurred on Wednesday, February 20th. The shares were sold at an average price of $57.41, for a total value of $2,275,502.76. Following the completion of the sale, the chief executive officer now owns 2,658,056 shares in the company, valued at approximately $152,598,994.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Christine Chung sold 11,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $46.41, for a total transaction of $522,112.50. Following the completion of the sale, the senior vice president now owns 163,562 shares of the company’s stock, valued at approximately $7,590,912.42. The disclosure for this sale can be found here. In the last 90 days, insiders sold 231,791 shares of company stock valued at $12,644,356. 8.96% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2019/05/11/fibrogen-fgen-issues-quarterly-earnings-results-beats-expectations-by-0-15-eps.html.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More: Balanced Fund

Earnings History for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.